Results 1 to 10 of about 603,389 (312)

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Paddle-to-Podium: a four-phased applied research model, translating research into practice for female surfers

open access: yesFrontiers in Sports and Active Living
The announcement of Teahupo’o, Tahiti as the location for surfing events at the Paris 2024 Olympic Games prompted a focus on performance research specific to female surfers. Following a 14-year absence of competitive female surfing at Teahupo’o, athletes
J. Parsonage   +11 more
doaj   +1 more source

Stability evaluation of high-order splitting method for incompressible flow based on discontinuous velocity and continuous pressure

open access: yesAdvances in Mechanical Engineering, 2019
In this work, we deal with high-order solver for incompressible flow based on velocity correction scheme with discontinuous Galerkin discretized velocity and standard continuous approximated pressure.
Liyang Xu   +5 more
doaj   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

open access: yesMolecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain   +10 more
wiley   +1 more source

Exploring Innovation Strategies that affect business performance in restaurants

open access: yes, 2011
This paper presents the initial results of a study exploring the nature of innovation in high performing restaurants and its role on business performance.
Wilkins, Hugh   +2 more
core  

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

open access: yesMolecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Dislocation loop and irradiation-induced synergistic-competitive mechanism in Cu-rich precipitates: a phase-field study

open access: yesScientific Reports
Both irradiation and dislocations have been proposed as routes to rationally manipulate spatial distribution and micromorphology of precipitate. An interesting effect emerges in Fe–10at.%Cu–3at.%Mn–1.5at.%Ni–1.5at.%Al alloy due to the synergistic ...
Wenkui Yang   +5 more
doaj   +1 more source

Instrumental and experiential attitudes toward (A.I.) augmented decision-making at work

open access: yesComputers in Human Behavior: Artificial Humans
In augmented decision-making, defined as a process wherein human judgment is complemented with decision-support systems powered by artificial intelligence (A.I.-DSS), employees are expected to monitor and sometimes override system outputs to enhance ...
Kees Maton   +3 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy